Literature DB >> 27873649

Antibacterial susceptibility of Escherichia coli among outpatients with community-acquired urinary tract infection in Hamadan, Iran.

Mojgan Mamani1, Niusha Nobari2, Mohammad Yousef Alikhani3, Jalal Poorolajal4.   

Abstract

Escherichia coli is the main cause of community-acquired urinary tract infections (UTIs). The aims of the present study were to examine the susceptibility profile of E. coli causing UTIs and to identify factors associated with antimicrobial resistance. A cross-sectional study was conducted in Hamadan City, Iran, between 2012 and 2013. Patients referred to Farshchian or Shahid Beheshti Hospitals and diagnosed with UTI caused by E. coli were enrolled in the study. Susceptibility testing to commonly used antimicrobial agents was performed by the disk diffusion method. Relevant data were abstracted, and analysis was performed to identify factors associated with antimicrobial resistance. A total of 154 patients were enrolled in the study. Among the respective number of E. coli isolates, the highest susceptibility was observed to nitrofurantoin (94.1%) and gentamicin (86.4%) and the lowest to amoxicillin/clavulanic acid (35.1%), trimethoprim/sulfamethoxazole (38.3%) and ciprofloxacin (51.9%). Twenty-four isolates (15.6%) were susceptible to all antimicrobial tested, 31 (20.1%) were resistant to one agent and 99 (64.3%) exhibited resistance to at least two different classes of antibiotics [multidrug-resistant (MDR) phenotype]. Patients with prior use of antibiotics during the past 3 months and those who had an episode of UTI in the past 2 years were at higher risk of being infected with MDR E. coli (P=0.034 and P=0.001, respectively). In conclusion, a substantial proportion of E. coli causing UTI exhibited a MDR phenotype. History of UTI and prior use of antibiotics were associated with increased risk of infection caused by MDR E. coli. Copyright Â
© 2015 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Drug resistance; Urinary tract infection; Uropathogenic Escherichia coli

Year:  2015        PMID: 27873649     DOI: 10.1016/j.jgar.2015.01.003

Source DB:  PubMed          Journal:  J Glob Antimicrob Resist        ISSN: 2213-7165            Impact factor:   4.035


  5 in total

1.  Antimicrobial Susceptibility Patterns of Escherichia coli among Tunisian Outpatients with Community-Acquired Urinary Tract Infection (2012-2018).

Authors:  Nawel Daoud; Manel Hamdoun; Hela Hannachi; Chedlia Gharsallah; Wiem Mallekh; Olfa Bahri
Journal:  Curr Urol       Date:  2020-12-18

2.  Antibiotic resistance pattern and phylogenetic groups of the uropathogenic Escherichia coli isolates from urinary tract infections in Hamedan, west of Iran.

Authors:  Somayeh Bakhtiari; Hassan Mahmoudi; Sara Khosravi Seftjani; Mohammad Ali Amirzargar; Sima Ghiasvand; Mohammad Ebrahim Ghaffari; Maryam Adabi
Journal:  Iran J Microbiol       Date:  2020-10

3.  In Vitro Control of Uropathogenic Microorganisms with the Ethanolic Extract from the Leaves of Cochlospermum regium (Schrank) Pilger.

Authors:  Danny Ellen Meireles Leme; Allan Belarmino Rodrigues; Adriana Araújo de Almeida-Apolonio; Fabiana Gomes da Silva Dantas; Melyssa Fernanda Norman Negri; Terezinha Inez Estivalet Svidzinski; Jonas da Silva Mota; Claudia Andrea Lima Cardoso; Kelly Mari Pires de Oliveira
Journal:  Evid Based Complement Alternat Med       Date:  2017-12-11       Impact factor: 2.629

4.  Antimicrobial Resistance among Community-Acquired Uropathogens in Mashhad, Iran.

Authors:  Mohammad Moein Vakilzadeh; Amirhossein Heidari; Ali Mehri; Matin Shirazinia; Fereshte Sheybani; Ehsan Aryan; HamidReza Naderi; Mona Najaf Najafi; Marjan Varzandeh
Journal:  J Environ Public Health       Date:  2020-10-05

5.  Oral Antibiotics in Clinical Development for Community-Acquired Urinary Tract Infections.

Authors:  Balaji Veeraraghavan; Yamuna Devi Bakthavatchalam; Rani Diana Sahni
Journal:  Infect Dis Ther       Date:  2021-08-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.